Table 2. Anti-HBs response after HB vaccination given at month 0, 1, and 6 among participants seronegative for HBsAg, anti-HBs, and anti-HBc at baseline.
| Time after dosing | vaccination history | <10 IU/L | 10–100 IU/L | ≥100 IU/L | GMC (IU/L) |
|---|---|---|---|---|---|
| Month 1 | All (n = 414) | 287 (69.3, 64.6–73.7) | 37 (8.9, 6.4–12.1) | 90 (21.7, 17.9–26.0) | 4.4 (3.3–5.9) |
| None (n = 43) | 33 (76.7, 61.4–88.2) | 3 (7.0, 1.5–19.1) | 7 (16.3, 6.8–30.7) | 3.3 (1.5–7.5) | |
| Confirmed (n = 41) | 25 (61.0, 44.5–75.8) | 5 (12.2, 4.1–26.2) | 11 (26.8, 14.2–42.9) | 8.4 (3.0–23.3) | |
| Unknown (n = 330) | 229 (69.4, 64.1–74.3) | 29 (8.8, 6.0–12.4) | 72 (21.8, 17.5–26.7) | 4.3 (3.1–5.9) | |
| P value | P1 = 0.6333 | P = 0.3029 | |||
| Month 6 | All (n = 407) | 33 (8.1, 5.6–11.2) | 166 (40.8, 36.0–45.7) | 208 (51.1, 46.1–56.1) | 95.8 (81.7–112.5) |
| None (n = 41) | 5 (12.2, 4.1–26.2) | 16 (39.0, 24.2–55.5) | 20 (48.8, 32.9–64.9) | 85.4 (48.7–149.9) | |
| Confirmed (n = 40) | 4 (10.0, 2.8–23.7) | 16 (40.0, 24.9–56.7) | 20 (50.0, 33.8–66.2) | 96.5 (58.8–158.2) | |
| Unknown (n = 326) | 24 (7.4, 4.8–10.8) | 134 (41.1, 35.7–46.7) | 168 (51.5, 46.0–57.1) | 97.1 (81.2–116.2) | |
| P value | P2 = 0.7910 | P = 0.8945 | |||
| Month 7 | All (n = 406) | 4 (1.0, 0.3–2.5) | 12 (3.0, 1.5–5.1) | 390 (96.1, 93.7–97.7) | 742.6 (680.5–810.2) |
| None (n = 41) | 0 (0, 0.0–8.6) | 5 (12.2, 4.1–26.2) | 36 (87.8, 73.8–95.9) | 611.6 (446.6–837.6) | |
| Confirmed (n = 41) | 0 (0, 0.0–8.6) | 1 (2.4, 0.1–12.9) | 40 (97.6, 87.1–99.9) | 815.0 (677.6–980.4) | |
| Unknown (n = 324) | 4 (1.2, 0.3–3.1) | 6 (1.9, 0.7–4.0) | 314 (96.9, 94.4–98.5) | 752.1 (680.8–830.9) | |
| P value | P > 0.9999 | P = 0.0066 | P = 0.0325 | P = 0.2957 | |
| Month 20 | All (n = 399) | 10 (2.5, 1.2–4.6) | 66 (16.5, 13.0–20.6) | 323 (81.0, 76.7–84.7) | 308.1 (268.2–354.0) |
| None (n = 32) | 0 (0, 0.0–10.9) | 6 (18.8, 7.2–36.4) | 26 (81.3, 63.6–92.8) | 444.8 (293.5–674.1) | |
| Confirmed (n = 37) | 0 (0, 0.0–9.5) | 6 (16.2, 6.2–32.0) | 31 (83.8, 68.0–93.8) | 325.4 (211.4–500.9) | |
| Unknown (n = 330) | 10 (3.0, 1.5–5.5) | 54 (16.4, 12.5–20.8) | 266 (80.6, 75.9–84.7) | 295.6 (252.8–345.5) | |
| P value | P3 = 0.9266 | P = 0.2852 |
Data are presented as participant number or value (proportion of participants and/or 95%CI). P1, P2, P3: comparison of anti-HBs distribution among the participants with confirmed, unknown or none vaccination history. At month 7 for 10–100 IU/L: P = 0.5689, 0.2012, 0.0039 for confirmed vs. unknown, confirmed vs. none, unknown vs. none, respectively. At month 7 for ≥100 IU/L: P > 0.9999, = 0.2012, = 0.0180 for confirmed vs. unknown, confirmed vs. none, unknown vs. none, respectively. For multiple comparison, Bonferroni adjustment was used with α = α/month = 0.05/3 = 0.0167.